Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Published: 18-Dec-2024
Regulatory Finance Pharmaceutical

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

You need to be a subscriber to read this article.
Click here to find out more.

Merck has entered into an exclusive global licensing agreement with Hansoh Pharma for its preclinical GLP-1 receptor agonist, HS-10535.

The orally administered small molecule bolsters Merck's current cardiometabolic pipeline, and aims to enhance the pharma giant's standing in this niche as GLP-1-targeting medication soar in popularity. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Merck MSD
See more

You may also like

Regulatory

Merck's sacituzumab tirumotecan granted Breakthrough Therapy Designation by the FDA

Read more
The antibody-drug conjugate (ADC) can be used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC)

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  2. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Merck's sacituzumab tirumotecan granted Breakthrough Therapy Designation by the FDA

The antibody-drug conjugate (ADC) can be used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Manufacturing

Merck bolsters its ADC CDMO offering with €71m Missouri manufacturing site expansion

The facility's expansion has tripled its ADC manufacturing capacity, bolstering Merck's CDMO offering for current and new clients
Regulatory

Merck gains EC approval for Winrevair to treat patients with pulmonary arterial hypertension

The drug significantly improved six minute walk distances, while also reducing risk of death or symptom worsening in the Phase III STELLAR trial
Research & Development

Merck acquires $700m clinical-stage bispecific antibody from Curon Biopharmaceutical

The CD3xCD19-targeting T-cell engager is currently being evaluated in Phase I/Ib/II clinical trials for a range of B-cell malignancies
Manufacturing

Merck and Daiichi Sankyo expand antibody drug conjugate commercialisation agreement

The companies will collaborate to commercialise MK-6070, a T-cell engager which has shown promise in treating patients with small cell lung cancer (SCLC)
Subscribe now